|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nascimento AV, Bousbaa H, Ferreira D and
Sarmento B: Non-small cell lung carcinoma: An overview on targeted
therapy. Curr Drug Targets. 16:1448–1463. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Holdenrieder S and Stieber P: New
challenges for laboratory diagnostics in non-small cell lung
cancer. Cancer Biomark. 6:119–121. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ramnath N, Dilling TJ, Harris LJ, Kim AW,
Michaud GC, Balekian AA, Diekemper R, Detterbeck FC and Arenberg
DA: Treatment of stage III non-small cell lung cancer: Diagnosis
and management of lung cancer, 3rd ed: American College of Chest
Physicians evidence-based clinical practice guidelines. Chest. 143
(Suppl 5):e314S–e340S. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ding X, Yang Y, Sun Y, Xu W, Su B and Zhou
X: MicroRNA-585 acts as a tumor suppressor in non-small-cell lung
cancer by targeting hSMG-1. Clin Transl Oncol. 19:546–552. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu X and Chen J: Advances in diagnosis
and treatment and whole process management of anaplastic lymphoma
kinase (ALK)-positive non-small cell lung cancer. Zhonghua Zhong
Liu Za Zhi. 37:1–4. 2015.(In Chinese). PubMed/NCBI
|
|
7
|
Rosell R and Karachaliou N: Lung cancer:
Maintenance therapy and precision medicine in NSCLC. Nat Rev Clin
Oncol. 10:549–550. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schnabel PA and Junker K: Neuroendocrine
tumors of the lungs. From small cell lung carcinoma to diffuse
idiopathic pulmonary neuroendocrine cell hyperplasia. Pathologe.
35:557–564. 2014.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li Z, Song Y, Liu L, Hou N, An X, Zhan D,
Li Y, Zhou L, Li P, Yu L, et al: miR-199a impairs autophagy and
induces cardiac hypertrophy through mTOR activation. Cell Death
Differ. 24:1205–1213. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mao M, Wu Z and Chen J: MicroRNA-187-5p
suppresses cancer cell progression in non-small cell lung cancer
(NSCLC) through down-regulation of CYP1B1. Biochem Biophys Res
Commun. 478:649–655. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Moretti F, D'Antona P, Finardi E, Barbetta
M, Dominioni L, Poli A, Gini E, Noonan DM, Imperatori A, Rotolo N,
et al: Systematic review and critique of circulating miRNAs as
biomarkers of stage I–II non-small cell lung cancer. Oncotarget.
8:94980–94996. 2017.PubMed/NCBI
|
|
12
|
Gompelmann D, Eberhardt R and Herth FJ:
Advanced malignant lung disease: What the specialist can offer.
Respiration. 82:111–123. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Donadeu FX, Schauer SN and Sontakke SD:
Involvement of miRNAs in ovarian follicular and luteal development.
J Endocrinol. 215:323–334. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liwak U, Faye MD and Holcik M: Translation
control in apoptosis. Exp Oncol. 34:218–230. 2012.PubMed/NCBI
|
|
16
|
Rutnam ZJ and Yang BB: The involvement of
microRNAs in malignant transformation. Histol Histopathol.
27:1263–1270. 2012.PubMed/NCBI
|
|
17
|
Wang N and Zhang T: Down-regulation of
microRNA-135 promotes sensitivity of non-small cell lung cancer to
gefitinib by targeting TRIM16. Oncol Res. 26:1005–1014. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jin JJ, Liu YH, Si JM, Ni R and Wang J:
Overexpression of miR-1290 contributes to cell proliferation and
invasion of non small cell lung cancer by targeting interferon
regulatory factor 2. Int J Biochem Cell Biol. 95:113–120. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gao X, Li S, Li W, Wang G, Zhao W, Han J,
Diao C, Wang X and Zhang M: MicroRNA-539 suppresses tumor cell
growth by targeting the WNT8B gene in non-small cell lung cancer. J
Cell Biochem. 120:2017.
|
|
20
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang J, Song C, Tang H, Zhang C, Tang J,
Li X, Chen B and Xie X: miR-629-3p may serve as a novel biomarker
and potential therapeutic target for lung metastases of
triple-negative breast cancer. Breast Cancer Res. 19:722017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jingushi K, Ueda Y, Kitae K, Hase H, Egawa
H, Ohshio I, Kawakami R, Kashiwagi Y, Tsukada Y, Kobayashi T, et
al: miR-629 targets TRIM33 to promote TGFbeta/Smad signaling and
metastatic phenotypes in ccRCC. Mol Cancer Res. 13:565–574. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Phuah NH, Azmi MN, Awang K and Nagoor NH:
Suppression of microRNA-629 enhances sensitivity of cervical cancer
cells to 1′S-1′-acetoxychavicol acetate via regulating RSU1. Onco
Targets Ther. 10:1695–1705. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hattori A, Takamochi K, Oh S and Suzuki K:
New revisions and current issues in the eighth edition of the TNM
classification for non-small cell lung cancer. Jpn J Clin Oncol.
49:3–11. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Araki K, Osaki M, Nagahama Y, Hiramatsu T,
Nakamura H, Ohgi S and Ito H: Expression of RUNX3 protein in human
lung adenocarcinoma: Implications for tumor progression and
prognosis. Cancer Sci. 96:227–231. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Torshabi M, Faramarzi MA, Tabatabaei Yazdi
M, Ostad SN and Gharemani MH: Runx3 expression inhibits
proliferation and distinctly alters mRNA expression of bax in AGS
and A549 cancer cells. Iran J Pharm Res. 10:355–361.
2011.PubMed/NCBI
|
|
28
|
Wang Y, Li Y, Wu B, Shi C and Li C:
MicroRNA-661 promotes non-small cell lung cancer progression by
directly targeting RUNX3. Mol Med Rep. 16:2113–2120. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee JM, Shin JO, Cho KW, Hosoya A, Cho SW,
Lee YS, Ryoo HM, Bae SC and Jung HS: Runx3 is a crucial regulator
of alveolar differentiation and lung tumorigenesis in mice.
Differentiation. 81:261–268. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee KS, Lee YS, Lee JM, Ito K, Cinghu S,
Kim JH, Jang JW, Li YH, Goh YM, Chi XZ, et al: Runx3 is required
for the differentiation of lung epithelial cells and suppression of
lung cancer. Oncogene. 29:3349–3361. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cortinovis D, Monica V, Pietrantonio F,
Ceresoli GL, La Spina CM and Wannesson L: MicroRNAs in non-small
cell lung cancer: Current status and future therapeutic promises.
Curr Pharm Des. 20:3982–3990. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Boeri M, Pastorino U and Sozzi G: Role of
microRNAs in lung cancer: microRNA signatures in cancer prognosis.
Cancer J. 18:268–274. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vannini I, Fanini F and Fabbri M:
MicroRNAs as lung cancer biomarkers and key players in lung
carcinogenesis. Clin Biochem. 46:918–925. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shao L, Shen Z, Qian H, Zhou S and Chen Y:
Knockdown of miR-629 inhibits ovarian cancer malignant behaviors by
targeting testis-specific Y-like protein 5. DNA Cell Biol.
36:1108–1116. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yan H, Li Q, Wu J, Hu W, Jiang J, Shi L,
Yang X, Zhu D, Ji M and Wu C: MiR-629 promotes human pancreatic
cancer progression by targeting FOXO3. Cell Death Dis. 8:e31542017.
View Article : Google Scholar : PubMed/NCBI
|
